$474 Million is the total value of Invesco Private Capital's 7 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 28.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NVGS | Navigator Holdings Ltd. | $251,435,000 | -28.8% | 21,863,874 | 0.0% | 53.08% | -15.7% | |
| SNBC | Sun Bancorp Inc. | $87,926,000 | -0.2% | 4,255,848 | 0.0% | 18.56% | +18.2% | |
| XCO | Exco Resources Inc. | $66,435,000 | +31.4% | 51,104,050 | 0.0% | 14.02% | +55.7% | |
| CACB | Buy | Cascade Bancorp | $63,591,000 | -2.9% | 11,478,529 | +0.1% | 13.42% | +15.0% |
| XENE | Xenon Pharmaceutical, Inc. | $2,575,000 | -15.6% | 436,384 | 0.0% | 0.54% | 0.0% | |
| FIT | New | Fitbit, Inc. | $1,206,000 | – | 98,693 | +100.0% | 0.26% | – |
| ZAYO | Zayo Group Holdings, Inc. | $522,000 | +15.2% | 18,705 | 0.0% | 0.11% | +35.8% | |
| ETSY | Exit | Etsy Inc. | $0 | – | -35,400 | -100.0% | -0.06% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NAVIGATOR HOLDINGS LTD. | 24 | Q3 2019 | 99.0% |
| Sun Bancorp Inc. | 19 | Q4 2017 | 35.4% |
| Exco Resources Inc. | 19 | Q4 2017 | 24.9% |
| XENON PHARMACEUTICALS, INC. | 18 | Q1 2019 | 1.0% |
| Cascade Bancorp | 16 | Q1 2017 | 20.3% |
| E2Open, Inc. Common Stock | 7 | Q4 2014 | 3.1% |
| Cyclacel Pharmaceuticals k | 7 | Q4 2014 | 0.1% |
| Talmer Bancorp Inc | 6 | Q2 2015 | 20.5% |
| LipoScience, Inc. Common Stock | 6 | Q3 2014 | 0.5% |
| Harmonic, Inc. Common Stock | 5 | Q2 2014 | 0.4% |
View Invesco Private Capital's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| E2open Inc | February 06, 2015 | 671,123 | 2.3% |
| CALLIDUS SOFTWARE INC | February 14, 2011 | 1,601,406 | 5.0% |
| MONTPELIER RE HOLDINGS LTDSold out | February 14, 2011 | 0 | 0.0% |
| Cyclacel Pharmaceuticals, Inc. | April 07, 2006 | 931,313 | - |
| SIGMATEL INC | February 11, 2005 | 447,881 | 1.3% |
| HEALTH GRADES INCSold out | March 12, 2003 | 0 | 0.0% |
| ALLOS THERAPEUTICS INC | October 02, 2002 | 861,961 | 3.8% |
| HEALTHGRADES COM INCSold out | March 23, 2001 | 0 | 0.0% |
| REPEATER TECHNOLOGIES INC | February 27, 2001 | 2,164,656 | 9.3% |
| TRANSGENOMIC INC | February 27, 2001 | 2,292,426 | 10.7% |
View Invesco Private Capital's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2019-12-05 |
| 4 | 2019-11-27 |
| 13F-HR | 2019-11-14 |
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 3 | 2019-04-08 |
| 13F-HR | 2019-02-14 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| 13F-HR | 2018-05-15 |
View Invesco Private Capital's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.